Structure Therapeutics Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Structure Therapeutics Inc. (GPCR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 23.79 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Structure Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 23.24M shares, a 27.63% increase year-over-year.
- Structure Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 18.21M shares, a 38.89% increase year-over-year.
- Structure Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 13.11M shares, a 8.94% increase year-over-year.
- Structure Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 12.04M shares, a 82.09% decline year-over-year.
- Structure Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 19.99M shares, a 44.18% increase from fiscal 2024.
- Structure Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 13.87M shares, a 15.49% increase from fiscal 2023.
- Structure Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 12.01M shares, a 84.01% decline from fiscal 2022.
- Structure Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 75.07M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 23.79M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 23.24M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 19.99M shares 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 18.84M shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 19.07M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 18.21M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 13.87M shares 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 13.59M shares 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 13.50M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 13.11M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 12.01M shares 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 11.89M shares 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 12.04M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 12.04M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 75.07M shares 10-K · filed 2024-03-08 | |||
| 2022-09-30 | 75.03M shares 10-Q · filed 2023-11-17 | |||
| 2022-06-30 | 75.33M shares 10-Q/A · filed 2023-11-17 | |||
| 2022-03-31 | 67.22M shares 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |